Project name: Expansion of Medical Retina Facilities at James Cook University Hospital
Joint working project summary: The principal aim of this joint working project, which comprises the expansion of the medical retina services in a new site at James Cook University Hospital, (the “Project”), is to deliver the benefits to patients of consistent care and improved outcomes for patients affected by Age-Related Macular Degeneration, (“AMD”), Diabetic Macular Oedema (“DMO”) and Retinal Vein Occlusion (“RVO”)); specifically, the Project aims at introducing clinics segmented by condition and by stability of condition so that patients will be seen within appropriate timescales and will benefit from an improved patient experience.
Expected Patient Outcomes for this Project:
Patients: - will be seen within appropriate timescales, which will ensure there is no avoidable loss of vision; - will benefit from improved patient experience due to clinic efficiencies (one stop-clinics, disease dedicated clinics).
Start Date and Duration: February 2018, for 15 months Project Period: February 2018 – May 2019
Imperial College Healthcare NHS Trust
Project Name: The Hammersmith Myeloproliferative Neoplasm Service Database Development Joint Working Project (JWP)
Joint Working Project Summary Hammersmith Hospital has an international reputation as a centre of excellence for the management of Myeloproliferative Neoplasms (MPN) and is part of the Imperial College Healthcare NHS Trust (“the Trust”). The Trust has seen a 6.8% surge in clinical activity and an increase in emergency admissions in 2015-16 and finished the year in financial deficit1. This growth in demand has been experienced at Hammersmith Hospital by the malignant haematology clinical team (“the NHS team”).The NHS team have recognised the need to gain a better understanding of these demands and pressures via the development and expansion of a current Hammersmith haematology departmental database.
Aims: Novartis and the NHS team will work together on a JWP which develops a current Hammersmith haematology departmental database. The NHS team will develop the database, provide clinical oversight and generate service level reports. Novartis will provide project management expertise and the resources for a NHS Service Pathway Manager. The service level reports will provide the ability to assess the MPN patient service pathway against various service pathway performance indicators such as the length of time patients wait in clinic, access to a Clinical Nurse Specialist (“CNS”) and holistic assessments, speed of access to blood results and patient satisfaction of the service. The service reports will also facilitate the NHS team to identify, implement and track the impact of new healthcare professional activities / interactions with MPN patients to improve patient care, service efficiency and patient centric support and advice.
A project steering group will regularly review and track the progress and impact of this JWP via the generation of aggregated service level reports. At 12 months from the start of the JWP there will be a review of its progress and if the objectives and milestones are being met the JWP will continue into the second year.
Novartis working in partnership with the NHS will gain a richer understanding of the MPN patient pathway service standards which the NHS teams work to. This will enrich Novartis discussions with other NHS sites / stakeholders when developing other JWPs.
Expected Patient Outcomes for this Project
An improved quality of care and quicker access to an enhanced MPN patient service pathway in terms of the following: • access to a CNS / key worker and 24 hour telephone advice line; • concerns and queries dealt with effectively by the NHS team; • reduced waiting time in clinic, bloods to be taken and the dispensing of medicine in pharmacy; • quicker access to updates from the NHS team on care and treatment plans; • provision of information to build knowledge of condition; • access to holistic assessments and sign-posting to other support roles such as psychological therapy.
Financial Contribution: As detailed in the Joint Working Agreement Start Date and Duration: Start date by the end of February 2018 with an expected duration to the end of February 2020. Project Period: 24 months